National Comprehensive Cancer Network
|
|||||
- Educational Events & Programs
- NCCN Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™
- NCCN Annual Congress: Hematologic Malignancies™
- NCCN Congress Series™
- NCCN Guidelines Update Webinar Series™
- NCCN Academy for Excellence & Leadership in Oncology™
- NCCN On-line CME/CE
- NCCN Library of Case Studies™
- NCCN Oncology Case Management Program™
- NCCN Oncology Policy Program
- NCCN International Programs
NCCN Guidelines® & Clinical Resources
NCCN Drugs & Biologics Compendium (NCCN Compendium™)
Transparency: Process and Recommendations
These documents will open in a new browser window.
Acute Myeloid Leukemia Panel
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Adult Cancer Pain Panel
Version 2.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Bladder Cancer Panel
Version 2.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Bone Cancer Panel
Version 1.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Breast Cancer Panel
Version 2.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 3.2010
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Breast Cancer Risk Reduction Panel
Version 3.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Central Nervous System Cancers Panel
Version 2.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Cervical/Uterine Cancers Panel
Version 2.2012 (Uterine Neoplasms)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011 (Uterine Neoplasms)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011 (Cervical Cancer)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Chronic Myelogenous Leukemia Panel
Version 1.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Colon/Rectal/Anal Cancers Panel
Version 2.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Esophageal/Gastric Cancers Panel
Version 2.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Hepatobiliary Cancers Panel
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Hodgkin Lymphoma Panel
Version 1.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 3.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Kidney/Testicular Cancers Panel
Version 1.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Melanoma Panel
Version 2.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 3.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Multiple Myeloma Panel
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Neuroendocrine Tumors Panel
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Non-Hodgkin`s Lymphomas Panel
Version 4.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 2.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Non-Melanoma Skin Cancer Panel
Version 1.2012 (Dermatofibrosarcoma Protuberans)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2012 (Basal Cell and Squamous Cell Skin Cancer)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011 (Basal Cell and Squamous Cell Skin Cancer)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Non-Small Cell Lung Cancer Panel
Version 1.2012 (Thymomas and Thymic Carcinomas)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2012 (Non-Small Cell Lung Cancer)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2012 (Malignant Pleural Mesothelioma)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 2.2011 (Non-Small Cell Lung Cancer)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011 (Non-Small Cell Lung Cancer)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011 (Malignant Pleural Mesothelioma)
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Ovarian Cancer Panel
Version 2.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Pancreatic Adenocarcinoma Panel
Version 1.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Prostate Cancer Panel
Version 3.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 3.2010
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 2.2010
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Small Cell Lung Cancer Panel
Version 1.2012
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Thyroid Carcinoma Panel
Version 2.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Version 1.2011
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
|
Minutes/Evidence | Panel Attendance | Panel Disclosures |
Disclaimer
The recommendations regarding the uses and indications in the NCCN Drugs & Biologics Compendium™ have been derived directly from the NCCN Clinical Practice Guidelines in Oncology™ which are a statement of consensus of the authors with respect to the scientific evidence and their expert views of appropriate treatments for patients with cancer. The NCCN Compendium neither represents an all-inclusive listing of every drug and biologic nor every use and indication for Drugs & Biologics. The listing of Drugs & Biologics in the Compendium is limited in consideration to a discussion of the uses of Drugs & Biologics in cancer care. NCCN considers clinical trials participation to be appropriate care. Any clinician seeking to apply or consult the NCCN Compendium is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment.
To order the latest flash drive of the Complete Library of NCCN Clinical Practice Guidelines in Oncology™, please click here
Privacy Policy| Legal Notices| Site Map| Contact Us| Help
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved